Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension

Cardiovascular Drugs and Therapy

Volumn 11, Issue 4, 1997, Pages 581-590

  Ruddy, Terrence D ^a   George Fodor, J ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Ambulatory blood pressure monitoring; Lisinopril; Nisoldipine; Systemic hypertension

Indexed keywords

LISINOPRIL; NISOLDIPINE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; NISOLDIPINE; TIME FACTORS;

EID: 9844239911     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007744005480     Document Type: Article

References (32)

1. Massie BM, Hirsch AT, Inouye IK, Tubau JF. Calcium channel blockers as antihypertensive agents. Am J Med 1984; 77(Suppl 4A):135-121.
2. Spivak C, Ocken S. Frishman WH. Calcium antagonists: Clinical use in the treatment of systemic hypertension. Drugs 1983;25:154-177.
3. Halperin AK, Cubeddu LX. The role of calcium channel blockers in the treatment of hypertension. Am Heart J 1986; lll;363-382.
4. Opie LH. Calcium channel antagonists: Part VII: Are second generation agents better? In Opie LH (ed). Drugs for the Heart. Philadelphia: WB Saunders, 1995:280-285.
5. Neumayer HH, Geliert J, Luft FE. Calcium antagonists and renal protection. Ren Fail 1993;153:353-358.
6. Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988;8:285-290.
7. Ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 1994; 154:1185-1202.
8. Brandt D. Calcium antagonists in the therapy of ventricular hypertrophy. Wien Med Wockenschr 1993;143:510-513.
9. Rosenthal T, Frohlich ED. Nisoldipine in the treatment of hypertension. Adv Ther 1993;10:151-156.
10. Man-in-t-Veld AJ. Calcium antagonists in hypertension. Am J Med 1989;86:6-14.
11. Nakaya H, Hattori Y, Nakao Y, Kanno M. Cardiac versus vascular effects of a new dihydropyridine derivative, CV4093. In vitro comparison with other calcium antagonists. Eur J Pharmacol 1988; 143:35-43.
12. Friedel HA, Sorkin EM. Nisoldipine: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficiency in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988;36=2-731.
13. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995;75:41E-45E.
14. Lewis BS. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemie ventricular dysfunction. Am J Cardiol 1995; 75:46E-53E.
15. Lang H, Christensen J. Long-term treatment of essential hypertension with lisinopril or a low-dose lisinopril/hydrochlorothiazide combination. Drug Dev Res 1995;(Suppl. 2):30-33.
16. Kiowski W, Osswald S. Circadian variation of ischemie car- diac events. J Cardiovasc Pharmacol 1993;21(Suppl. 2);S45-S48.
17. Graney WF. Clinical experience with a once-daily, extendedrelease formulation of diltiazem in the treatment of hypertension. Am J Med 1992:93(Suppl. 2A) ∋ S-65S.
18. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993: 328:914-21.
19. Weir MR, Josselson J, Giard MJ, et al. Sustained-release diltizem compared with atenolol monotherapy for mild to moderate systemic hypertension. Am J Cardiol 1987; 60:361-411.
20. Murdoch D, Brogden RN. Sustained-release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991; 41:737-779.
21. Carruthers SG, Vint-Reed C. Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Clin Invest Med 1993;16:386394.
22. Ruddy TD, Wright JM, Savard D, et al. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. Cardiovasc Drugs Ther 1995;9:413-420.
23. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478-505.
24. Thurston H, Mimran A, Zanchetti A, et al. A double-blind comparison of perindopril and atenolol in essential hypertension. J Hum Hyperten 1990;4:547-552.
25. Friedel HA, Sorkin EM. Nisoldipine-a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficiency in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drug 1988;36:682-731.
26. Zanchetti A, Bianchi L, Bozza M, et al. Antihypertensive effects of nifedipine GITS on clinic and ambulatory blood pressure in essential hypertensives. High Blood Pressure 1994;3=-46.
27. Guntzel P, Kobrin I, Pasquier C, et al. The effect of cilazapril, a new antiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. J Cardiovasc Pharmacol 1991;17:8-12.
28. Myers MG. Use of trough: Peak ratio in the assessment of antihypertensive drug therapy. Can J Cardiol 1994; 10(Suppl. D):17D-20D.
29. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologie indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharmacol Ther 1988;44:540-545.
30. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken when prescribed? A novel assessment technique. JAMA 1989;261:3272-3277.
31. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patients medication compliance. Arch Intern Med 1990;150:1881-1884.
32. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.